Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Cantor Fitzgerald
Deloitte
Cipla
Citi
Mallinckrodt
Johnson and Johnson
UBS

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,225,474

« Back to Dashboard

Which drugs does patent 6,225,474 protect, and when does it expire?

Patent 6,225,474 protects ULORIC and is included in one NDA.

This patent has fifty-five patent family members in thirty-four countries.
Summary for Patent: 6,225,474
Title: Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
Abstract:The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.
Inventor(s): Matsumoto; Koichi (Iwakuni, JP), Watanabe; Kenzo (Iwakuni, JP), Hiramatsu; Toshiyuki (Iwakuni, JP), Kitamura; Mitsutaka (Higashi-Hiroshima, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:09/485,861
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,225,474
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,225,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,225,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-173079Jun 19, 1998
PCT Information
PCT FiledJune 18, 1999PCT Application Number:PCT/JP99/03258
PCT Publication Date:December 23, 1999PCT Publication Number: WO99/65885

International Family Members for US Patent 6,225,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 449765 ➤ Try a Free Trial
Austria 522512 ➤ Try a Free Trial
Australia 4289299 ➤ Try a Free Trial
Australia 748026 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Medtronic
US Army
Chinese Patent Office
McKesson
Harvard Business School
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.